CIDP Diagnostic Criteria and Response to Treatment

  • Charles Roach Washington University in St. Louis
  • Mazen Dimachkie University of Kansas Medical Center
  • Jeffrey Statland University of Kansas Medical Center
  • Richard Barohn University of Missouri
  • Omar Jawdat University of Kansas Medical Center
  • Arthur Dick University of Kansas Medical Center
  • Andrew Heim University of Kansas Medical Center
  • Mamatha Pasnoor University of Kansas Medical Center
Keywords: Chronic Inflammatory Demyelinating Polyneuropathy, Retrospective Chart Review, Diagnostic Criteria, Treatment Response, IVIG, EFNS/PNS


Introduction: Diagnostic criteria for CIDP have been proven useful for clinical trials. However, use of these criteria in clinics has been limited by time constraints and unknown usefulness in predicting outcomes.
Methods: A retrospective chart review of CIDP patients at the University of Kansas seen between 2008 and 2014 was performed. We determined the diagnostic criteria fulfilled by each patient and assessed treatment responses. A positive response was defined by improvement sensory or motor examination as determined by a neuromuscular physician.
Results: There were 38 total patients included in the study. The response rate to IVIG in patients who fulfilled EFNS/PNS criteria was 20/22 (90.1%). Among patients who fulfilled AAN criteria, 8/9 (88.9%) responded positively to IVIG. Slightly lower response rates were seen in patients fulfilling INCAT criteria and Saperstein criteria at 10/15 (66.7%) and 12/17 (70.6%), respectively.
Discussion: EFNS/PNS and AAN criteria can similarly predict IVIG treatment response.


1. Amin R, Robertson N. Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Neurol. 2015;262(3):789-791. doi: 10.1007/s00415-015-7667-x.
2. Joint Task Force of the EFNS/PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Journal of the peripheral nervous system: Journal of the Peripheral Nervous System 2005; 10:220-228.
3. Rajabally, Y. A., Jacob, S. and Abbott, R. J. (2006), Clinical heterogeneity in mild chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology, 13: 958–962. doi: 10.1111/j.1468-1331.2006.01403.x
4. Breiner A, Brannagan TH 3rd, Comparison of Sensitivity and Specificity Among 15 Criteria for Chronic Inflammatory Demyelinating Polyneuropathy. Muscle and Nerve. 2014 Jul;50(1):40-6. doi: 10.1002/mus.24088. Epub 2013 Dec 11.
5. Hughes RA1, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA; ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurology, 2008 Feb;7(2):136-44. doi: 10.1016/S1474-4422(07)70329-0.
6. Kuwabara S, Mori M, Misawa S on behalf of the Glovenin-I CIDP Study Group, et al. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
J Neurol Neurosurg Psychiatry 2017;88:832-838.
How to Cite
Roach, C., Dimachkie, M., Statland, J., Barohn, R., Jawdat, O., Dick, A., Heim, A., & Pasnoor, M. (2020). CIDP Diagnostic Criteria and Response to Treatment. RRNMF Neuromuscular Journal, 1(2), 7-10. Retrieved from
New Discoveries/New Stuff (Original Research)